

## Stenting the unprotected left main coronary artery- mid-term outcomes of the observational registry.

**Professor Samir Rafla**, FACC, FESC, [smrafla@yahoo.com](mailto:smrafla@yahoo.com) 01001495577 0000-0001-8688-6532

Professor of Cardiology, Alexandria University, Egypt, Corresponding author: Address 398 Abo Kir street, Mostafa Kamel, 21321, Alexandria, Egypt

**Amr Zaki**, [amrtonzaki@yahoo.com](mailto:amrtonzaki@yahoo.com) 01223935434  
0122 311 5753 Professor of Cardiology, Alexandria University, Egypt

**Mohamed Ibrahim Loutfi** [drmloutfi@yahoo.com](mailto:drmloutfi@yahoo.com) 01001442346  
Professor of Cardiology, Alexandria University, Egypt

**Mohamed Ahmed Sadaka** [mohsadaka2000@yahoo.com](mailto:mohsadaka2000@yahoo.com) 01227498471 0000 0001 6752 9337  
Professor of Cardiology, Alexandria University, Egypt

**Moataz Shebl** [moatazshebl@gmail.com](mailto:moatazshebl@gmail.com) 01006454811 0000-0001-6310-8412  
[moatazshebl@yahoo.com](mailto:moatazshebl@yahoo.com) Cardiologist, Alexandria University, Egypt

Address for all authors, Alexandria University, Faculty of Medicine, Cardiology Department, Azarita, 32123, Alexandria, Egypt

### Abstract

**Background:** The results of stenting the unprotected left main coronary artery (UPLM) without IVUS but with meticulous care need to be studied more.

**Methods:** This prospective and retrospective study was performed in multiple local centers. The local ethics committee approved the study, and the patients signed informed consent. The local heart team, including a cardiac surgeon, was consulted for a joint decision agreement. In the last five years, one hundred twenty patients with left main disease > 50% were subjected to stenting with drug-eluted stents.

All patients were subjected to history taking; 12 lead ECGs were revised. An echocardiographic examination and laboratory tests were done.

Risk assessment was calculated including Euro SCORE and Syntax score. Patient selection: Consecutive patients arriving for primary Stenting or acute coronary episode were included.

**Medications:** All patients received clopidogrel and aspirin before the planned procedure. Anticoagulation with unfractionated heparin in a dose of 10000 IU was given at the beginning of the PCI. Post PCI, all patients received the guidelines recommended drugs. *Calcification* was assessed by angiographic imaging only. *We estimated the vessel diameter* as 2/3 diameter of the branches. A steerable guidewire was advanced in LAD, followed by PCI with pre-dilatation or direct Stenting according to the operator's discretion. One or two stent strategy was utilized according to the situation of the lesions.

Results: 92 patients (77.3%) presented with ACS, of which 65 patients (54.6%) had no Previous Intervention, and 27 patients (22.7%) had a previous PCI. Left ventricular ejection fraction significantly correlates with the complication at six months follow-up; all 16 patients with reported complications (100%) had baseline LVEF of < 40 % (P< 0.023). Syntax score: 11 patients (55%) with a high score of more than 32 had adverse events, P= 0.004. Residual syntax shows a less significant correlation with a mean value of 7.3 in the complication group versus 4.9 in the other group (P = 0.016). Final kissing balloon inflation shows no statistically significant difference. Conclusions: PCI in UPLM is a safe, feasible option with a high technical success rate and acceptable outcome at follow-up, even without the utilization of IVUS

*Ethical committee protocol number 0208221*

**Keywords:** Left main coronary artery stenosis, drug-eluted stents, SYNTAX score, IVUS, PCI

## Introduction

Clinical trials demonstrated a higher rate of reintervention after coronary percutaneous intervention (PCI) compared with coronary artery bypass grafting (CABG). PCI had a lower incidence of cerebrovascular events. <sup>(1-21)</sup>

Current guidelines recommend CABG as class I for most patients with LM <sup>(3, 4)</sup>. New features in stent technology, revascularization techniques, and antithrombotic medications make PCI safer. PCI with DES implantation for LMCA disease has dramatically increased in daily clinical practice.

Detailed examination of the anatomic size of LM lesions is achieved using intravascular ultrasound (IVUS) [22]. IVUS helps determine the vessel size, lumen area, plaque extent, and calcification within the LMCA. IVUS is of value to ensure stent optimization of LMCA PCI. The use of IVUS guidance is associated with improved clinical outcomes after the procedure

Aim of the work: The study was designed to evaluate the short and mid-term clinical outcomes of elective, unprotected left main coronary artery stenting in multiple local centers. The feasibility of stenting UPLMD without IVUS needs to be studied to determine if this is possible in centers not equipped with IVUS.

## Methods

This prospective and retrospective study was performed in multiple local centers. The local ethics committee approved the study, and the patients signed informed consent.

In the last five years, one hundred twenty patients with left main disease > 50% were subjected to stenting with drug-eluted stents.

All patients were subjected to detailed history taking with particular emphasis on the acute coronary syndrome, angina duration, class, previous coronary interventions, and medications. In addition, 12 lead ECGs were revised with an evaluation of ST/T changes and any old infarction. An echocardiographic examination was done on all patients following the recommendations of

the American Society of Cardiology [23]. Ejection fraction, LV diameters, and wall motion were recorded. Laboratory testing included kidney function, lipid profile, and blood sugar.

Risk assessment was calculated for every patient, including Euro SCORE and Syntax score.

Patient selection: Consecutive patients arriving for primary stenting or acute coronary episode were included.

Exclusion criteria: Patients with pulmonary edema, advanced renal insufficiency, advanced COPD (Chronic obstructive pulmonary Disease), and patients referred for surgery,

Medications: All patients received clopidogrel and aspirin before the planned procedure. Anticoagulation with unfractionated heparin in a dose of 10000 IU was given at the beginning of the PCI. Post PCI, all patients received B blockers, ACE inhibitors, statins, and dual antiplatelets in the guidelines recommended doses.

PCI technique: A steerable guidewire was advanced in LAD, followed by PCI with pre-dilatation or direct stenting according to the operator's discretion (according to prediction of possible calcification, then predilation was opted to). One or two stent strategy was utilized according to the situation of the lesions (31-35).

Although we know that IVUS is the standard method to determine calcification, *calcification*: was assessed by angiographic imaging

*We assessed vessel diameter as 2/3 diameter of the branches*

## Study outcomes

### 1. Procedural outcomes:

- a) Thrombolysis in Myocardial Infarction (TIMI) flow grade was graded Grade 0, absence of antegrade flow beyond the point of occlusion; Grade1, partial penetration of contrast agent beyond the obstruction but incomplete distal filling; Grade 2, patency with opacification of the entire distal vessel but with delayed filling or washout of contrast agent; and Grade 3, normal flow.
- b) We defined the procedural success rate as residual stenosis of less than 20% and establishment of Thrombolysis in Myocardial Infarction (TIMI)-3 flow. Without major periprocedural adverse events (Death, myocardial infarction, emergency revascularization).

### 2. In-hospital outcomes

- A. Death. B. Myocardial infarction. C. Cerebrovascular stroke. D. Re-intervention: Target Vessel Revascularization (TVR), Target Lesion Revascularization (TLR), and Non-Target Vessel Revascularization (Non- TVR). E. Heart Failure.

### 3. Thirty days outcomes

- a. Death. B. New angina or myocardial infarction. C. Cerebrovascular stroke.

- d. Re-intervention: (TVR), (TLR), and (Non- TVR). E. Heart Failure.
- a. We recorded six-month outcomes as death, cerebrovascular stroke, re-intervention (TVR), (TLR), and (Non- TVR), New angina, and Heart Failure.

**Study endpoints:** Primary endpoints are major cardiovascular events at 30 days and six months, defined as death, myocardial infarction, cerebrovascular stroke, and re-intervention: TVR, TLR, and Non-TVR.

All methods were performed following the relevant guidelines and regulations

#### **Statistical analysis of the data**

Data were fed to the computer and analyzed using IBM SPSS version 20.0. (Armonk, NY: IBM Corp) Qualitative data were described using numbers and percentages. The Kolmogorov-Smirnov test was used to verify the normality of distribution. Quantitative data were described using range (minimum and maximum), mean, standard deviation, and median. The significance of the obtained results was judged at the 5% level. The used tests were: Chi-square test: For categorical variables to compare different groups. Fisher's Exact or Monte Carlo correction: Correction for chi-square when more than 20% of the cells have an expected count of less than 5. Student t-test: For normally distributed quantitative variables, to compare two studied groups.

#### **Results**

This prospective study included 50 patients undergoing elective percutaneous coronary intervention for unprotected left coronary artery disease in Alexandria. In addition, a retrospective arm included 70 patients who had left main stenting in the last five years.

The study included 120 patients, 88 males and 32 females, with a mean age of 61.

Regarding risk factors, we found that diabetes was the most common risk factor present in 95 patients (79.2%), followed by hypertension in 83 patients (69.2%), 69 patients were current smokers (57.5%), and dyslipidemia in 60 patients (50%).

Regarding clinical presentation, we found that 92 patients (77.3%) presented with ACS, of which 65 patients (54.6%) had no previous intervention, and 27 patients (22.7%) had a prior PCI. One patient with previous CABG, Patients with a chronic coronary syndrome, were 27 (22.7%), and none of the chronic coronary syndrome patients had an earlier intervention. As shown in table (1)

#### **Anatomical characteristics:**

According to coronary angiography, we determined the following anatomical characteristics:

- a) CAD extent, whether non-distal LM disease (ostial and shaft) or a distal bifurcation or trifurcation

- b) Left circumflex dominance.
- c) Bifurcation angle between LAD, LCX
- d) Ostial LCX significant disease as shown in table (2).

**PCI characteristics:**

We classified the patients according to the following PCI Characteristics:

- a) Access either femoral (101 patients) or radial (19 patients).
- b) We used Guiding catheters to cannulate LMCA. 6F in 53 patients, 7F in 67.
- c) LM stent number.
- d) The technique used for stenting (Provisions-Cullotte-SKS-TAP-Minicrush, DK crush)**
- e) POT and Final kissing done or not?
- f) Diameter and length of the LM stent.
- g) Other stents (s) are used to treat other lesions.
- h) Total stents number
- i) We calculated the residual syntax score (Table 3)

**Complications:** Procedural, In-hospital, one-month, and six months complications were documented, including access site hematoma, contrast nephropathy, dissection, heart failure, bleeding, TLR, non-TLR, Angina, ACS, stroke, and Death. As shown in (Tables 4-8)

**Statistical relation with different complications:**

**a) Demographic data**

**The study included 120 patients**

There was no statistically significant difference between the procedural and in-hospital complications regarding sex (p-value = 0.46) and age group (p-value = 0.52). Still, at one-month follow-up, 9 out of 12 complications were more than 60 years, and only three were below 50 years (P-value = 0.024); at six months, there were no significant correlations between age, sex, and adverse events.

**b) Risk Factors**

As regards the risk factors, only the hypertension group showed statistically significant increased complications, where 17 out of 20 complications were in hypertensive subjects (85% with P-value =

0.093); this finding was consistent at one-month follow-up where all 12 patients with complications were hypertensive (100%) (P-value = 0.017) and to less extent at six months follow up eight patients out of 16 cases with complications were hypertensive (P-value = 0.087)

Diabetes and presentation (acute vs. CCS) were not significantly correlated with complication rate, P-value =0.76 for DM and 0.77, the same finding at one month and six months of follow-up.

**C) LV function**


Left ventricular ejection fraction significantly correlated with procedural and in-hospital complications, with 12 patients out of 20 who had reduced LVEF by Less than 40 % (P-value = 0.033); at one month, LVEF was not significantly associated with complications, yet at six months follow up all 16 patients with reported complications (100%) had baseline LVEF of less than 40 % (P-value = 0.023)

**1- Angiographic and procedural characteristics:**

**a) Syntax score**

Statistically significant correlation between Syntax score and adverse outcome with a higher score, one patient out of 20 (5%) had a lower score than 23. In contrast, eight patients with intermediate scores had adverse events, and 11 patients (55%) with a high score of more than 32 had adverse events with a P-value of 0.004; the mean syntax score in the complication group was 32.3 Vs. 27.6 in the group with no complications (P-value 0.006), Syntax II Score was significantly higher in the complication group 36.24 Vs. 27.26 in The group without complications (P value<0.001), Residual syntax shows a less significant correlation with a mean value of 7.3 in the complication group versus 4.9 in the other group (P value= 0.016) (Table 7), Fig 1—relation between complications and Syntax I.

Fig 1 Relation between complications and Syntax I



At One month, the Syntax score still correlates with adverse events where the Mean syntax I score was 31.76 in the complication group Vs. 28 in the other Group (P-value 0.07), and Syntax II PCI a mean of 38.47 in the complication Group Vs. 27.69 in another group, the residual syntax score shows again statistically significant differences at one month with a mean of 10.75 in complication Vs. 4.77 in another group (P-value = 0.018) but not at six months follow-up between the complication group and the other group

**b) LCX**

Neither LCX dominance nor significant ostial disease showed a statistically significant correlation with the adverse events during in-hospital and follow-up periods, as well as the angle between LAD and LCX in this study

**c) Kissing**

Final kissing balloon inflation shows no statistically significant difference compared to non-kissing regarding complications, procedural in-hospital, and follow-up period.

**d) Other stents**

Implantation of more than one stent shows no statistically significant differences compared to the single stent regarding complications, procedural in-hospital, and follow-up period.

Follow up: was done by patient's reexamination with history, ECG, Echo. No new coronary angiography were done except in six patients who had new chest pains . The left main stent was found to be patent or not restenosed in all. Multislice CT was done instead of coronary angio in five patients, also left main stent were found not restenosed.

**Discussion**

The present study evaluated the feasibility of stenting LMCA without IVUS.

We successfully treated one hundred twenty such patients with drug-eluting stents. The percentage of complications was not inferior to the incidence when IVUS was utilized. Thus the strategy of stenting LMCAD without these techniques is safe and effective when performed by experienced interventional cardiologists (22-31).

We followed all patients in a cardiology outpatient clinic one month after PCI, followed by a visit or phone call after six months, and then after one year. No routine angiography was performed unless symptomatic or positive stress test; 24 patients had exercise testing during the follow-up period, four were positive, and fifteen patients had follow-up angiography either following a positive stress test or ACS.

In our study, the mean age of the patients was 60 years; this is six years younger than the mean age in the EXCEL trial, in which the mean age was 66.5 years; this may reflect the earlier or aggressive atherosclerotic cardiovascular burden.

Lee HM, et al. in their study concluded that Simple crossover LM-to-LAD stenting without opening of a strut on the LCX ostium was associated with acceptable long-term clinical outcomes (24).

As regards other demographic criteria in our study predominant male sex (73.3%) was shared in different left main trials; in the Indian registry published in the Indian heart journal by Ray et al., 2016 (25), around 76% of the patients were male, of note the mean age was 60 years in this registry.

In our study, neither the age nor the sex had influenced the outcome, including MACE at one-year follow-up significantly; still, at one-month follow-up, the reported complications were higher (9 patients out of 12) more than 65 years, and only three were below than 50 years (29,30).

Worth mentioning recent systematic review, published in Cardiovascular Revascularization Medicine Journal in 2020 shows that women who undergo PCI for unprotected LMCD are at higher risk of MACE and MI compared to men such finding was not validated in our study primarily due to relatively small sample size (37).

As regards the risk factors and their relation to complications in our study, only hypertension had a statistically significant association with the adverse outcome, unlike DM, dyslipidemia, and smoking. These findings correlate with results published before (25).

The SYNTAX I score is one of our study's most important predictors of MACE. The mean syntax score in the complication group was 32.3 Vs. 27.6 in the group with no complications (P-value 0.006). The same finding was reproducible at one month and six months outcome these findings consider revalidation of the value of SYNTAX score I as one of the most important prognostic factors in UPLM PCI. Capodanno Et al. found that the SYNTAX score is an important tool to suggest cardiac mortality and MACE in patients undergoing percutaneous revascularization of the left main coronary artery even at short and mid-term follow-up at one year. (27)

As regards the SYNTAX II score, it showed statistically significant results concerning MACE in our study. Syntax II Score was significantly higher in complication group 36.24 Vs. 27.26 in The group without complications (P value<0.001). This finding comes in agreement with a study published by Madeira et al. from Portugal in 2016 titled Potential Utility of the SYNTAX Score II in Patients Undergoing Left Main Angioplasty over 132 patients undergoing UPLM PCI and concluded that The SYNTAX Score II might allow better and individualized risk stratification of patients who need revascularization of an unprotected left main coronary artery The authors suggested that a difference more significant than 5.7% between SYNTAX Score 2 estimates for PCI versus CABG may be clinically relevant in selecting the optimal revascularization strategy (28)



Another important prognostic factor in our study is the residual syntax score (RSS) which was significantly higher in the complication group at one month, with a mean of 10.75 in complication Vs. However, 4.77 in another group (P-value = 0.018) was less significant at one-year follow-up; the value of RSS in many trials did not address UPLM PCI specifically.

Another important angiographic criterion that shows significance is the location of the left main lesion. Ostial LM lesion PCI in our study, when compared to the distal site, offers a significantly lower incidence of MACE that was evident at one-year follow-up, where 10% of the distal LM PCI showed complication versus no reported complications in the ostial LM PCI group (P value=0.001). This finding agrees with Hyun et al.'s essential registry in 2020<sup>(30)</sup>.

Regarding the procedural characteristics, there was no significant difference in MACE in our study between the 2-stent strategy, including different techniques of 2-stent strategies and one stent during the follow-up period. This is shown in The Milan and New-Tokyo Registry published by Takagi et al. in 2016, and they compared one versus two stents strategy in UPLMD in more than nine hundred and thirty patients in three different centers. The main issue observed was more TLR in single stent strategy, but no significant mortality difference; needless to say, ostial compromise of side branch ostium (whether LAD or LCX) is among the critical reasons for increased side branch revascularization, but as they concluded, it did not affect mortality (31-36)

## **CONCLUSIONS**

- 1) PCI in unprotected left coronary artery disease is a possible option with a high technical success rate and acceptable outcome at follow-up when IVUS is unavailable.
- 2) The following parameters were associated with increased MACE rate in our study: Hypertension as a risk factor was associated with an increased risk of complication at follow-up; elevated SYNTAX score; distal left main lesion location versus ostial and mid-shaft; reduced left ventricular ejection fraction; residual SYNTAX score as a marker of incomplete revascularization
- 3) Risk stratification is crucial for strategy selection in managing LMCAD patients based on current validated anatomic and physiologic complexity scores.
- 4) Absence of assisting imaging techniques, namely IVUS, is not prohibitive to practicing UPLM PCI, as demonstrated in our study, despite its valuable role in stent optimization.

*Limitations of the study:* IVUS is the standard method now for optimization of stenting of the left main coronary artery. When it is not available, and in urgent cases, we cannot ignore the possibility of trying stenting without IVUS. So this study throughs light on this possibility. The size of the main artery was calculated as 2/3 of the sum of the branches two or three. Finally, balloon reinflation was resorted to ensure sufficient strut deployment. Follow of six months and one year is not sufficient, but this does not validate the results.

*DK crush* was not used in the beginning. Mini crush was used at first

#### Abbreviations

ACS: Acute coronary syndrome

BMS: Bare metal stent

CIN: Contrast-induced nephropathy

CABG: Coronary artery bypass graft

CAD: Coronary artery disease

CCS: Chronic coronary syndrome

CTO: Chronic total occlusion

DES: Drug-eluting stent

ISR: In-stent restenosis

IVUS: Intravascular ultrasound

LMCAD: Left main coronary artery disease

LMB: Left main bifurcation

LAD: Left anterior descending

LCX: Left circumflex

MACE: Major adverse cardiac event

PCI: Percutaneous coronary intervention

LVEF: Left ventricular ejection fraction

STEMI: ST-elevation myocardial infarction

NSTEMI: Non-ST elevation myocardial infarction

TLR: Target lesion revascularization

TVR: Target vessel revascularization

#### 'Declarations'

-Ethics approval and consent to participate: The local ethics committee: The Ethical Committee of the Faculty of Medicine Alexandria University, number 00012098, approved the study. We obtained **informed consent**: written/verbal permission from the patient or the patient's parent/carer. All methods followed relevant guidelines and regulations (Declaration of Helsinki).

-Consent for publication: All authors consent for publication

-Availability of data and materials. The datasets used or analyzed during the current study are available from the corresponding author upon request.

-Competing interests: None. Conflict of interest: The authors declare no conflict of interest in

preparing this article

-Funding: None

-Authors' contributions:

AZ, involved in the study concept, design, and stenting

ML engaged in the study's conception, design, and stenting

MS, involved in the study concept, design, and stenting

SR was involved in writing the paper and submitting it. All authors contributed to the writing—original draft preparation and approved the final version.

-Acknowledgements: All the nursing staff, technicians, and residents

#### **Availability of data and materials**

Data sharing does not apply to this article as no datasets were generated or analyzed during the current study. Data and master charts are available with Dr. MS

- Funding: This research received no specific grant from any public, commercial, or not-for-profit funding agency.
- Conflict of interest: The authors declare no conflict of interest in preparing this article.

We obtained written consent from the local Ethics Committee: The Ethical Committee of the Faculty of Medicine Alexandria University, number 00012098

We obtained consent: written/verbal permission from the patient or the patient's parent/carer.

Institutional Review Board Approval number 00012098

#### References

1. Jennifer S. Lawton, Jang B. Jaswal, Jacqueline E. Tamis-Holland, Paul A. Kurlansky, Roxana Mehran, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC VOL. 79, NO. 2, 2022
2. Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson<sup>1</sup>, Fernando Alfonso, Adrian P. Banning. Et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal (2019)40, 87–165
3. Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 2009; 120(15):1505-12.
4. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med 2017; 376(19):1824-34.
5. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between

Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation* 2010; 121(24):2645-53.

6. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with Taxus and cardiac surgery trial. *Circulation* 2014; 129(23):2388-94.

7. Buszman PE, Buszman PP, Banasiewicz-Szkrobka I, Milewski KP, Zurakowski A, Orlik B, et al. Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial. *JACC Cardiovasc Interv* 2016; 9(4):318-27.

8. Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. *J Am Coll Cardiol* 2015; 65(20):2198-206.

9. Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomized, open-label, non-inferiority trial. *Lancet* 2016; 388(10061):2743-52.

10. Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, et al. Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study. *J Am Coll Cardiol* 2013; 61(14):1482-8.

11. Chen SL, Zhang JJ, Han Y, Kan J, Chen L, Qiu C, et al. Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial. *J Am Coll Cardiol* 2017; 70(21):2605-17.

12. Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *N Engl J Med* 2016; 375(23):2223-35.

13. Bing R, Yong AS, Lowe HC. Percutaneous Transcatheter Assessment of the Left Main Coronary Artery: Current Status and Future Directions. *JACC Cardiovasc Interv* 2015; 8(12):1529-39.

14. Serruys PW, Farooq V, Vranckx P, Girasis C, Brugaletta S, Garcia-Garcia HM, et al. A global risk approach to identify patients with the left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. *JACC Cardiovasc Interv* 2012; 5(6):606-17

15. Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, et al. Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. *J Am Coll Cardiol* 2016; 68(10):999-1009.

16. Song YB, Hahn JY, Yang JH, Choi SH, Choi JH, Lee SH, et al. Differential prognostic impact of treatment strategy among patients with left main versus non-left main bifurcation

- lesions undergoing percutaneous coronary intervention: results from the COBIS (Coronary Bifurcation Stenting) Registry II. *JACC Cardiovasc Interv* 2014; 7(3):255-63.
17. D'Ascenzo F, Iannaccone M, Giordana F, Chieffo A, Connor SO, Napp LC, et al. Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity-matched analysis. *Int J Cardiol* 2016; 211:37-42.
18. Palmerini T, Marzocchi A, Tamburino C, Sheiban I, Margheri M, Vecchi G, et al. Impact of bifurcation technique on 2-year clinical outcomes in 773 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents. *Circ Cardiovasc Interv* 2008; 1(3):185-92.
19. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Yoon SH, et al. Temporal trends in revascularization strategy and outcomes in left main coronary artery stenosis: data from the ASAN Medical Center-Left MAIN Revascularization registry. *Circ Cardiovasc Interv* 2015; 8(3):e001846.
21. Sheiban I, Moretti C, D'Ascenzo F, Chieffo A, Taha S, Connor SO, et al. Long-Term (>=10 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. *Am J Cardiol* 2016; 118(1):32-9.
22. Kang SJ, Ahn JM, Song H, Kim WJ, Lee JY, Park DW, et al. Comprehensive intravascular ultrasound assessment of stent area and its impact on restenosis and adverse cardiac events in 403 patients with the unprotected left main disease. *Circ Cardiovasc Interv* 2011; 4(6):562-9.
23. Kubo S, Kadota K, Sabbah M, Otsuru S, Hasegawa D, Habara S, et al. Clinical and angiographic outcomes after drug-eluting stent implantation with a triple-kissing-balloon technique for left main trifurcation lesion: comparison of single-stent and multi-stent procedures. *J Invasive Cardiol* 2014; 26(11):571-8.
24. Lee HM, Nam CW, Cho YK, Yoon HJ, Park HS, Kim H, et al. Long-term outcomes of simple crossover stenting from the left main to the left anterior descending coronary artery. *Korean J Intern Med* 2014; 29(5):597-602.
25. Ray S, Mazumder A, Kumar S, Bhattacharjee P, Rozario D, Bandyopadhyay S, et al. Angioplasty of unprotected left main coronary stenosis: Real-world experience of a single-operator group from eastern India. *Indian Heart J* 2016; 68(1):28-35.
26. Hu FB, Tamai H, Kosuga K, Kyo E, Hata T, Okada M, et al. Predictors of improvement in left ventricular function after initially successful angioplasty of unprotected left main coronary artery stenoses. *Int J Cardiovasc Intervent* 2004; 6(3-4):119-27.
27. Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C, Tamburino C. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. *Circ Cardiovasc Interv* 2009; 2(4):302-8.

28. Madeira S, Raposo L, Brito J, Rodrigues R, Gonçalves P, Teles R, et al. Potential Utility of the SYNTAX Score 2 in Patients Undergoing Left Main Angioplasty. *Arq Bras Cardiol* 2016; 106(4):270-8.
29. Yoon YH, Ahn JM, Kang DY, Park H, Cho SC, Lee PH, et al. Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease. *JACC Cardiovasc Interv* 2020; 13(3):361-71.
30. Hyun J, Kim JH, Jeong Y, Choe K, Lee J, Yang Y, et al. Long-Term Outcomes After PCI or CABG for Left Main Coronary Artery Disease According to Lesion Location. *JACC Cardiovasc Interv* 2020; 13(24):2825-36.
31. Takagi K, Naganuma T, Chieffo A, Fujino Y, Latib A, Tahara S, et al. Comparison Between 1- and 2-Stent Strategies in Unprotected Distal Left Main Disease. *Circulation: Cardiovascular Interventions* 2016; 9(11):e003359.
32. Mitchell C., Rahko P.S., Blauwet L.A., et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2019 Jan;32(1):1-64..  
<https://doi.org/10.1016/j.echo.2018.06.004>
33. Levine GN, Bates ER, Blankenship JC, et al.. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation.* 2011; 124:e574–651.
34. Glenn N. Levine, Eric R. Bates, James C. Blankenship, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *J Am Coll Cardiol.* 2016 Mar, 67 (10) 1235–1250
35. Stephan Windecker, Franz-Josef Neumann, Peter Jüni, Miguel Sousa-Uva, Volkmar Falk. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. *European Heart Journal*, Volume 40, Issue 2, 07 January 2019, Pages 204–212, <https://doi.org/10.1093/eurheartj/ehy532>
36. Sangwoo Park, Seung-Jung Park, and Duk-Woo Park. Percutaneous Coronary Intervention for Left Main Coronary Artery Disease: Present Status and Future Perspectives OPEN ACCESS. *JACC: Asia.* 2022 Apr, 2 (2) 119–138
37. A. Thandra, A. Jhand , R. Guddeti , V. Pajjuru , M. DelCore , C.J. Lavie , et al.

Sex Differences in Clinical Outcomes Following Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine: Volume 28, July 2021, Pages 25-31 <https://doi.org/10.1016/j.carrev.2020.07.038>

Tables all

Table (1): Clinical, ECG, and ECHO characteristics of the studied cases (n = 120)

	No.	%
<b>Presentation</b>		
Acute	92	77.3
DiNovo ACS	65	54.6
ACS (Previous intervention)	27	22.7
CCS (No previous intervention)	27	22.7
<b>ECG</b>		
Normal resting	40	33.3
Diffuse ST depression/raising aVR	36	30.0
ST elevation	6	5.0
Left BBB	8	6.6
Atrial fibrillation	1	0.8
<b>Stigmata of previous infarction</b>		
Anterior Q waves	20	16.0
Inferior Q waves	9	7.5
<b>ECHO</b>		
Severe MR	5	4.1
RWMA	50	41.6
<b>ECHO (LVEF) (%)</b>		
Min. – Max.	25.0 – 75.0	
Mean ±SD.	49 ± 12	
<b>EURO score (%)</b>		
0 –3	100	84.0
3 –5	12	10.1
>5	7	5.9

Table (2): Angiographic characteristics (n = 120)

	No.	%
<b>CAD extent</b>		
Non-distal	19	15.8
<b>Distal</b>	<b>101</b>	<b>84.2</b>

Bifurcation	94	78.3
Trifurcation	7	5.8
<b>LCX dominance</b>		
No	90	75.0
Yes	30	25.0
<b>Ostial LCX significant disease</b>		
No	70	58.3
Yes non-dominant LCX	35	29.1
Yes dominant LCX	15	12.5
<b>Bifurcation angle</b>		
<70	92	76.7
>70	28	23.3
<b>Number of diseased vessels</b>		
1	19	15.8
2	65	54.1
3	36	30
<b>Presence of calcification</b>	55	45.8
<b>Presence of thrombi</b>	39	32.5
<b>RCA lesion</b>	29	24.1
<b>Medina classification (Distal LM)</b>		
1,0,0	11	10.8
0,1,0	0	0
1,1,0	33	32.6
0,0,1	0	0
1,0,1	12	11.88
0,1,1	0	0
1,1,1	45	44.5
<b>Syntax I</b>		
<23	17	14.3
23 –32	73	61.3
>32	29	24.4
Mean ±SD.	28.37 ± 6.53	

Table (3): Procedural characteristics of the studied population (n = 120)

PCI characteristics	No.	%
<b>LM stent type:</b> <b>Xience Xpedition/Alpine/V/Prime</b>	76	63.33
<b>Promus Element /Element plus/premiere</b>	12	10



<b>Biomatrix</b>	10	8.3
<b>Taxus Liberte</b>	8	6.66
<b>Onyx</b>	6	5
Other stents (Osirio-Eucalimus-Isaar-Ultimaster)	8	
<b>-Technique (n=120)</b>		
<b>Predilatation</b>	<b>85</b>	<b>70.8</b>
<b>One stent</b>	<b>87</b>	<b>72.5</b>
Provisional	71	59.2
Direct (non-distal lesions)	16	13.3
<b>Two stents</b>	<b>33</b>	<b>27.9</b>
Culotte	14	11.9
SKS	3	2.5
TAP	13	11.0
Mini crush (DK crush)	3	2.5
<b>Post-stenting balloon dilatation</b>		
POT	53	44.1
Re POT	22	18.3
<b>Final kissing</b>		
No	65	54.2
Yes	55	45.8
<b>IVUS guidance</b>	0	0
<b>Length</b> Min. – Max. (Mean ±SD).	8.0 – 48.0 ( 27.8 ± 10.4)	
<b>Diameter</b> Min. – Max. (Mean ±SD.)	3.5 – 5 (4 ± 0.5)	
Median (IQR)	3.5 (3.50–4.0)	
<b>Other vessels treated</b>		
1 vessel	59	49.2
2 vessels	35	29.1
3 vessels	7	5.8
<b>Residual syntax</b> Min. – Max. (Mean ±SD.)	0.0 – 24 (5.3 ± 6.3)	
Median (IQR)	4.0 (0.0–8.0)	

Table (4): Distribution of the studied cases according to complications (n=120)

	Complications					
	Procedural & In hospital		One month		Six months	
	No.	%	No.	%	No.	%
No	100	83.3	108	90.0	104	86.7

Yes	20	16.7	12	10.0	16	13.3
-----	----	------	----	------	----	------

Table (5): Distribution of the studied cases according to complications (n=120)

Complication	No.	%
Procedural		
Access site hematoma	8	6.6
PCI complications (dissection)	2	1.66
In hospital		
CIN (contrast Induced Nephropath)	3	2.5
Heart failure	7	5.8
One month		
Heart failure	3	2.5
Bleeding	4	0.83
Angina	3	2.5
Non- TLR	1	0.83
Stroke	1	0.83
Six months- One year follow up		
TLR	2	1.66
Non- TLR	4	3.33
Follow-up exercise test	24 (20)	20 (16.6)
Follow up angiography	15	12.5
ACS/CCS	6	5
Death	2	1.66
LVEF improvement	12	10

Table (6): Distribution of the studied cases according to total MACE during follow-up (n=120)

	No.	%
Death	2	1.7
Nonfatal ACS	6	5.0
TLR	2	1.7

Combined (Death / ACS /TLR)	10	8.3
Non-TLR	5	4.2
Stroke	1	0.8
Heart failure	7	5.8
CABG referral	0	0.0

Table 7: Relation between complications (in hospital) and different parameters

	Complications (in hospital)		P
	No (n = 100)	Yes (n = 20)	
Positive DM (%)	78 (78%)	85.0 (0.7%)	0.763
Positive HYPERTENSION	66 (66%)	85.0 (0.09%)	0.093
Presentation	(n = 99)	(n = 20)	
Acute	77 (77.8%)	75.0	0.775
CCS	22 (22.2%)	25.0	
ECHO (LVEF) (%)			
<40	17	60.0	0.033*
≥40	83	40.0	
Positive LCX dominance	29	5.0	0.024*
Ostial LCX significant disease	40	50.0	0.408
Bifurcation angle			
<70	77	75.0	0.781
>70	23	25.0	
Kissing	47	40.0	0.566
Access-Femoral	83	90.0	0.737
Access-Radial	17	10.0	
Other stents	60	70.0	0.401
Syntax I	27.63 ± 6.54	32.03 ± 5.26	0.006*
Syntax II (PCI) Number (%)	27.2 ± 7.5 (6.5+4.9)	36.2 ± 8.6 (13.8+11.5)	<0.001*
Syntax II (CABG) Number (%)	27.7± 10.4 (7.3+6.7)	36.2± 10.7 (16.2+13)	0.003*
Residual syntax	4.98 ± 6.58	7.30 ± 4.73	0.016*

Table 8: Relation between Complications (six months) and different parameters

	Complications (six months)		P
	No (n =104) (%)	Yes (n = 16) %	
Positive DM	83 (79.8%)	75.0	0.741
Positive HYPERTENSION	75 (72.1%)	50.0	0.087

<b>Presentation</b>	<b>(n =103)</b>	<b>(n =16)</b>	
Acute	80 (77.7%)	75.0	0.757
CCS	23 (22.3%)	25.0	
<b>ECHO (LVEF) (%)</b>			
<40	25 (24%)	100.0	0.023*
≥40	79 (76%)	0.0	
<b>Positive LCX dominance</b>	24 (23.1%)	37.5	0.226
<b>Ostial LCX significant disease</b>	42 (40.4%)	50.0	0.468
<b>Bifurcation angle</b>			
<70	82 (78.8%)	62.5	0.201
>70	22 921.2%)	37.5	
<b>Kissing</b>	47 (45.2%)	50.0	0.719
<b>Access</b>			
Femoral	85 (81.7%)	100.0	0.072
Radial	19 918.3%)	0.0	
<b>Other stents</b>	64 961.5%)	62.5	0.941
<b>Syntax I</b>	28.82 ± 5.93	25.44 ± 9.29	0.149
<b>Syntax II (PCI)</b>			
Number	29.4 ± 8.3	24.5 ± 7.8	0.029*
%	8.1 ± 7.3	5.4 ± 3.4	0.066
<b>Syntax II (CABG)</b>			
Number	30.2 ± 10.7	22.6 ± 10.2	0.023*
%	9.4± 9.1	5.0 ± 3.2	0.095
<b>Residual syntax</b>	5.3 ± 6.6	5.8 ± 3.9	0.241